HURA
TuHURA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.14
+1.90%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.6x
Market Cap
$136.37M
MomentumView details →
1D Return
+1.90%
YTD Return
+179.58%
RSI (14)
47.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.6x
Market Cap
$136.37M
RSI (14)
47.6
MomentumView details →
1D Return
+1.90%
YTD Return
+179.58%
SummaryUpdated Jun 1, 2026
TuHURA Biosciences, Inc. (NASDAQ:HURA) is a clinical-stage biotechnology company founded in 2013 and headquartered in Tampa, Florida. The company focuses on developing novel immuno-oncology therapies designed to overcome resistance mechanisms that limit the effectiveness of current cancer immunotherapies. TuHURA has progressed to phase 3 registration-stage trials, representing a significant milestone in bringing potentially life-saving cancer treatments to market.
Similar companies
Latest newsMore news →
Parabilis Medicines, Inc. appointed Craig Tendler, M.D., as a director, effective August 22, 2026, and granted him a stock option to purchase 20,294 shares of common stock at an exercise price of $39.36 per share.11d agoTuHURA Biosciences, Inc. issued 1,878,287 shares of common stock to Parkview Holdings One LLC as a loan fee in connection with a $50 million revolving credit facility, relying on Section 4(a)(2) and/or Regulation D exemptions.17d ago